VSTM•benzinga•
Verastem Oncology Announces Updated Data From Dose Escalation Phase Of The Phase 1/2 Trial Of GFH375; Study Shows ORR Of 52% In Patients With Pancreatic Ductal Adenocarcinoma And ORR Of 42% With Non-Small Cell Lung Cancer
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga